Analysis of the inhibition of liver fibrosis by interferon beta administration

Analysis of the inhibition of liver fibrosis by interferon beta administration - The strategy for the control of liver fibrosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005746

Enrollment

Registered

2011-07-01

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis and liver cirrhosis type C

Interventions

interferon beta administration glycyrrhizin administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis C (F2, F3), liver cirrhosis C

Exclusion criteria

Exclusion criteria: 1. HIV infection 2. the patients who were performed liver transplantation 3. decompensated liver cirrhosis 4. autoimmuno hepatitis, alcoholic liver injury 5. pancytepenia (neutrophil<1500mm3, platelet<50000mm3, Hb<8g/dl) 6. autoimmuno disease and collagen disease 7. severe complication; renal disorder, severe diabates, pulmonary fibrosis, retinal hemorrhage 8. allergy for vaccination 9. allergy for drug and food 10. psychological disorder for example, depression 11. the patients who are not suitable for entry in this study by physician

Design outcomes

Primary

Measure	Time frame
Improvement of the grade of liver fibrosis and biological marker for liver fibrosis (albmine, prothrombin time)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026